Antimicrobial Resistance (AMR), according to the World Health Organisation, is one of the top 10 threats facing humanity today. In this episode, we step into the public health arena and speak to Abigail Herron, Global Head of ESG Strategic Partnerships at Aviva Investors. Abigail is co-founder of the Superbugs and Super Risks series of events and reports for investors and is heavily involved in the AMR space. We delve into why AMR is a systemic risk, why investors should care and how they can act.
Antimicrobial Resistance (AMR): the systemic risk investors should be talking about
